Evidence map›Paper›PMID 28919061›Full record

Trial reportThe lancet. Diabetes & endocrinology2017

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.

Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde, DEPICT-1 Investigators

Erratum issued Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05541484 (Ketone Monitoring in T1D), which is not on this map. Cited by 143 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05541484 phase4completedstarted 2022, after this paper: background citation

Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency

Ran2022Enrolled21Registered outcomes3Posted comparisons1ConditionsDiabetes Mellitus, Type 1ArmsBiosense Breath Ketone Analyzer, SGLT2 inhibitor
PMID 30026335PMID 10634967PMID 30129772PMID 21725144PMID 25691653PMID 6818074PMID 33027776PMID 33024634PMID 32641376PMID 29068709other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Paresh DandonaDepartment of Medicine, State University of New York at Buffalo, Buffalo, NY, USA. Electronic address: pdandona@kaleidahealth.org.
Chantal MathieuClinical and Experimental Endocrinology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium.
Moshe PhillipSchneider Children's Medical Center of Israel, Institute for Endocrinology & Diabetes, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Lars HansenBristol-Myers Squibb, Princeton, NJ, USA.
Steven C GriffenJDRF, New York, NY, USA.
Diethelm TschöpeDepartment for Endocrinology, Diabetology & Gastroenterology, Heart and Diabetes Centre, Bad Oeynhausen, Germany; Ruhr University Bochum, Bochum, Germany.
Fredrik ThorénAstraZeneca, Mölndal, Sweden.
John XuAstraZeneca, Gaithersburg, MD, USA.
Anna Maria LangkildeAstraZeneca, Mölndal, Sweden.
DEPICT-1 Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes.

methodsDEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18-75 years and had inadequately controlled type 1 diabetes (HbA

findingsBetween Nov 11, 2014, and April 16, 2016, 833 patients were assigned to treatment groups and included in safety analyses (dapagliflozin 5 mg [n=277] vs dapagliflozin 10 mg [n=296] vs placebo [n=260]; 778 of these patients were randomly assigned and included in the full analysis set for efficacy analyses (259 vs 259 vs 260; difference due to randomisation error affecting 55 patients). Mean baseline HbA

interpretationOur results suggest that dapagliflozin is a promising adjunct treatment to insulin to improve glycaemic control in patients with inadequately controlled type 1 diabetes.

fundingAstraZeneca and Bristol-Myers Squibb.

Indexed as

AdultBenzhydryl CompoundsBody WeightDiabetes Mellitus, Type 1Drug Therapy, CombinationFemaleGlucosidesGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinMaleMiddle AgedTreatment OutcomeBenzhydryl CompoundsdapagliflozinGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulin

Identifiers

PMID28919061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.